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Figure 1. Radiographs of the medial meniscus. Left: Radiograph of medial
meniscus of the left knee (non-operated knee) of the guinea pigs. The
anterior horn was severely calciﬁed or ossiﬁed (arrow). Right: Radio-
graphs of medial meniscus of right knee (surgery performed knee) of the
guinea pigs. The severely ossiﬁed anterior horn was absent, removing by
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albeit further studies needs to validate this.MRI subpopulation: Demographic characteristics in intent-to-treat population [n(%) and mean (SD)]
2301sCTN¼278 2301PlaceboN¼273 2302sCTN¼155 2302PlaceboN¼152 AllsCTN¼433 AllPlaceboN¼425
Sex - n( %)
Male 84 (30%) 97 (36%) 63 (41%) 68(45%) 147 (34%) 165 (39%)
Female 194 (70%) 176 (64%) 92 (59%) 84 (55%) 286(66%) 260 (61%)
Age (years) 64.6 (6.9) 64.1(6.4) 65.0 (7.1) 64.4 (7.0) 64.8(7.0) 64.2 (6.6)
Race- n( %)
White 277 (100%) 272 (100%) 155 (100%) 151 (99%) 432 (100%) 423 (100%)
Other 1 (0%) 1 (0%) -(-) 1(1%) 1 (0%) 2 (0%)
BMI (kg/m2) 29.0 (4.1) 28.7 (4.1) 28.6 (4.0) 28.6 (4.2) 28.8(4.1) 28.7 (4.1)
JSW (mm)1 3.38 (0.95) 3.35 (0.94) 3.31 (1.07) 3.48 (1.01) 3.35(0.99) 3.39 (0.96)
KL index n (%)1
Grade 2 241 (87%) 245 (90%) 121(78%) 125 (82%) 362 (84%) 370 (87%)
Grade 3 37 (13%) 28 (10%) 31 (22%) 27 (18%) 71 (16%) 55 (13%)
WOMAC pain (mm)1 233 (72) 242 (69) 238 (66) 237 (63) 237 (70) 241 (67)
WOMAC total (mm)1 1089(379) 1135 ( 376) 1014 (377) 993(370) 1062(379) 1084 (380)
Cartilage volume tibial (mm3)1 2111 (503) 2196 (547) 2177 (559) 2200 (592) 2134 (524) 2198 (563)
Cartilage volume femoral (mm3)1 4903(1118) 5110 (1134) 5087 (1108) 5132 (1142) 4969 (1117) 5118 (1136)
Cartilage volume total (mm3)1 7013 (1543) 7305 (1599) 7264 (1590) 7332 (1652) 7103 (1563) 7314 (1617)
the partial-meniscectomy surgery (arrow).658
PHOSPHOCITRATE REDUCED CARTILAGE DEGENERATION IN NON-
CALCIFICATION INDUCED OSTEOARTHRITIS
Y. Sun, N. Haines, A. Roberts, M. Ruffolo, D. Mauerhan, J. Ingram,
M. Cox, E. Hanley. Carilinas Med. Ctr., Charlotte, NC, USA
Purpose: It was believed that phosphocitrate (PC) exerted its disease
modifying effect on calciﬁcation-induced osteoarthritis (OA) by inhib-
iting the formation of calcium crystals within the joints. However,
recent studies suggest that PC exerts its disease modifying effect on OA,
at least in part, through a crystal-independent mechanism. This study
sought to investigate the disease-modifying effect of PC on partial-
meniscectomy induced OA or non-calciﬁcation induced OA and test the
hypothesis that PC is not only potentially a disease modifying drug for
calciﬁcation-induced OA therapy but also potentially a disease-mod-
ifying drug for non-calciﬁcation-inducted OA therapy.
Methods: Male Hartley guinea pigs of 4 weeks old were subjected to
intraperitoneal injections of PC and physiological saline respectively.
Two months later, partial medial meniscectomy was performed on the
right knee of all guinea pigs to remove the anterior horn (calciﬁcation
site) of the medical meniscus. After the surgery, injections of PC and
saline were resumed. Five months later, these guinea pigs were
euthanized and hind limbs were collected. Meniscal calciﬁcation and
cartilage degeneration was examined with digital x-ray, Indian ink and
safranin O staining. Matrix metaloproteinse-13 (MMP-13), ADAM
metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5),chemokine (C-C motif) ligand 5 (CCL5), cyclooxygenase 2 (Cox-2) and
type X collagenwere examined with immunostaining. Results were are
expressed as the mean ± standard deviation. The differences between
PC-treated and untreated groups were analyzed using Student’s t test or
Wilcoxon rank sum test.
Results:Meniscal calciﬁcation in themedial meniscus was absent in the
partial-meniscectomy performed right knees. PC treatment sig-
niﬁcantly reduced the severity of cartilage degeneration and cartilage
thinning in the partial-meniscectomy induced OA or non-calciﬁcation-induced OA. The reductions in cartilage degeneration and cartilage
thinning were accompanied with signiﬁcantly decreased protein levels
of MMP-13, ADAMTS5 and CCL5.
Conclusions: PC is not only potentially a disease modifying drug for
calciﬁcation-induced OA therapy but also potentially a disease-mod-
ifying drug for non-calciﬁcation-inducted OA therapy. PC exerts its
disease modifying activity on non-calciﬁcation-induced OA mainly by
targeting the production of extracellular matrix-degrading enzymes
through a crystal-independent mechanism. These ﬁndings provide
further support for the development of PC or its analogues as disease-
modifying drugs for human OA therapy.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416A396Figure 2. Mean histological scores of the tibia plateaus. Left bar group:
Mean histological scores of the medial tibia plateaus of the rights knees in
the untreated and PC-treated guinea pigs. Right bar group: Mean histo-
logical scores of the lateral tibia plateaus of the right knees in the
untreated and PC-treated guinea pigs. * ¼ P < 0.05 PC-treated versus the
untreated guinea pigs.
Figure 3. Cartilage thickness. Left: thickness of the medial tibia cartilage in
the untreated guinea pigs. Right: thickness of the medial tibia cartilage in
the PC-treated guinea pigs.
Figure 4. Immunostaining scores. Left bar group: MMP-15 immunostain-
ing. Middle bar group: ADAMTS5 immunostaining. Right bar group: CCL-5
immunostaining.
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THE IN VIVO AND IN VITRO EFFECT OF INHIBITORS OF BRD4 AND
CDK9 ON EARLY PHASE OF POST TRAUMATIC OSTEOARTHRITIS
T. Fukui, J.H. Yik, D.R. Haudenschild. Lawrence J. Ellison Musculoskeletal
Res. Ctr., Sacramento, CA, USA
Purpose: Joint trauma is a risk factor for osteoarthritis (OA), and about
50% of patients with ACL or meniscal injury develop posttraumatic OA
(PTOA) within 10-20 years. The acute response to joint trauma increases
transcription of pro-inﬂammatory cytokines and proteinases such as
matrix metalloproteinases (MMPs), which trigger the onset of OA
changes. Bromodomain protein 4 (Brd4) and cyclin-dependent kinase 9
(CDK9) control the rate-limiting step of the transcription of primary
response genes, including most pro-inﬂammatory genes, by positively
regulating mRNA elongation with phosphorylating and releasing the
RNA polymerase II. The purpose of this study is to investigate the effects
of small molecule inhibitors of Brd4 (JQ1) and CDK9 (Flavopiridol) on
the activation of inﬂammatory genes using chondrocytes and cartilage
tissue under inﬂammatory stimuli, and a mouse PTOA model.
Methods:
 Treatment of chondrocytes Human chondrocytes were cultured 5
hours with inﬂammatory stimuli (either 10ng/ml IL1b, 10ng/ml TNFa, or
100ng/ml IL6 and 60ng/ml IL6 receptor), with or without drugs.
Treatment conditions were: 1) vehicle only (Ctrl), 2) no drug with
cytokine, 3) Hi JQ1 (1200nM) with cytokine, 4) Hi Flavopiridol (250nM)
with cytokine, 5) Combination of Lo JQ1 (250nM) and Lo Flavopiridol
(60nM) with cytokine. Total RNA was extracted and analyzed by real
time RT-PCR and microarray. Treatment of cartilage explants
Bovine cartilage explants were isolated and randomly assigned to 5
groups cultured as described above, with the cytokine being 10ng/ml
IL1b. Glycosaminoglycan (GAG) released into the culture media was
measured.
 PTOA animal model
The right knees of mice were injured with a mechanical compression,
which causes rupture of the anterior cruciate ligament and leads to
PTOA. Immediately after injury, mice were treated daily with JQ1 and/or
Flavopiridol. Treatment conditions were: 1) vehicle only (Ctrl), 2) Hi JQ1
(50mg/kg), 3) Hi Flavopiridol (7.5mg/kg), 4) Combination of Lo JQ1
(17mg/kg) and Lo Flavopiridol (2.5mg/kg) Flavopiridol.
 MMPSense Assay
To assess MMP activity, MMPSense 750 was injected to mice and the
intensity of signal from the MMPSense in the knees was measured by in
vivo imaging.
Results:
 The mRNA expression levels of pro-inﬂammatory genes (iNOS, Cox2)
and catabolic genes (MMP-1, -3, -9, and -13, and ADAMTS4) were sig-
niﬁcantly induced by all 3 inﬂammatory cytokines, and this induction
was suppressed by all 3 drug treatments. The combination of both drugs
at lower doses suppressed gene expression similarly or more strongly
than single high doses of each individual drug.
Microarray showed that expression, 873 geneswere induced >1.5-fold
by IL1b compared to baseline. IL-1b treatment in the presence of either
JQ1 or Flavopiridol alone prevented the induction of many genes.
However, a combination of both drugs prevented the induction of most
IL-1b response genes. (Fig.1)
 IL1b treatment of cartilage explants induced signiﬁcant release of GAG
within 3-6 days. GAG release was effectively prevented when IL-1b
treatment in the presence of either or both drugs. (Fig2)
 In PTOAmouse model, knee injury caused signiﬁcant increases of IL1b
and IL6 expression in the injured joint. All 3 treatments showed effect to
prevent increases of these cytokines and drug combination was more
effective than single drugs. (Fig3A, B) MMP activity in injured knee was
suppressed by all 3 treatment similarly at 24h and 48h after injury.
(Fig3C, D)
Conclusions: JQ1 and Flavopiridol are each able to effectively repress a
panel of pro-inﬂammatory and catabolic genes in chondrocytes induced
by inﬂammatory stimulus. We found that the combination of the 2
drugs showed a synergistic interaction, with similar or better repression
achieved at reduced drug doses. Although previous reports indicated
that Brd4 and CDK9 control mRNA transcription by regulating a com-
mon checkpoint, microarray analysis showed that there were also
inﬂammatory genes only affected by each drug individually. Ex vivo and
in vivo study also demonstrated the combination of lower dose of the
drugs has similar or better intensity of effect. This indicates that using
both drugs together may be able to suppress inﬂammation after trauma
with preventing side effects induced by overdose, leading to novel
treatment for PTOA.
